Digital mammography’s latest vendor, Siemens Medical Solutions, is showing its new Mammomat Novation system on the 2004 RSNA exhibit floor. The product meets all the demands of modern mammography practices, providing digital screening, diagnosis, and stereotactic biopsy capabilities. Since receiving FDA approval in August, Novation has been installed at 10 sites, and the company expects to install another 20 by year-end.
Digital mammography's latest vendor, Siemens Medical Solutions, is showing its new Mammomat Novation system on the 2004 RSNA exhibit floor. The product meets all the demands of modern mammography practices, providing digital screening, diagnosis, and stereotactic biopsy capabilities. Since receiving FDA approval in August, Novation has been installed at 10 sites, and the company expects to install another 20 by year-end.
"The marketplace was waiting for this system and this technology, and there's been great acceptance so far," said Erica Rouleau, national sales director for the company's Women's Health Division.
Versatility is a major selling point for Novation. The full-field digital mammography system features a tungsten x-ray tube, which the company claims facilities optimal image quality with 60% dose reduction. The system interfaces with Siemens' new MammoReport Plus, a dedicated mammography reading station, also being shown at the meeting.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.